Vascular closure devices: the second decade.
Vascular closure devices (VCDs) introduce a novel means for improving patient comfort and accelerating ambulation after invasive cardiovascular procedures performed via femoral arterial access. Vascular closure devices have provided simple, rapid, and reliable hemostasis in a variety of clinical settings. Despite more than a decade of development, however, VCD utilization has neither been routine in the U.S. nor around the world. Their limited adoption reflects concerns of higher costs for cardiac procedures and a lack of data confirming a significant reduction in vascular complications compared with manual compression. Recent data, however, suggest that VCD are improving, complication rates associated with their use may be decreasing, and their utilization may improve the process of care after femoral artery access. Challenges in the second decade of VCD experience will include performing definitive randomized trials, evaluating outcomes in higher-risk patients, and developing more ideal closure devices.
Dauerman
Harold L
HL
Division of Cardiology, University of Vermont College of Medicine, Burlington, Vermont 05401, USA. harold.dauerman@vtmednet.org
Applegate
Robert J
RJ
Cohen
David J
DJ
D000925:Anticoagulants / Q000627:therapeutic use; D006328:Cardiac Catheterization / Q000009:adverse effects*; D003362:Cost-Benefit Analysis; D004867:Equipment Design / Q000379:methods; D005544:Forecasting; D006470:Hemorrhage / Q000209:etiology* / Q000628:therapy*; D006489:Hemostatic Techniques / Q000191:economics / Q000295:instrumentation* / Q000639:trends*; D006801:Humans; D018579:Patient Selection; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D016896:Treatment Outcome; D014656:Vascular Surgical Procedures / Q000191:economics / Q000295:instrumentation* / Q000639:trends
D000925:Anticoagulants; D010975:Platelet Aggregation Inhibitors